Entinostat was discovered to sensitise HER2-positive BC cells to trastuzumab/lapatinib treatment, supporting the use of entinostat/lapatinib and trastuzumab in HER2-positive BC patients. This evidence concerns the gene ERBB2 and breast cancer.